Breaking News

BioSpectra Launches Contract Manufacturing Services

July 24, 2014

Opens new FDA-registered facility in Bangor, PA

BioSpectra, Inc. has launched contract manufacturing services for pharma and biopharma products from its new FDA-registered facility in Bangor, PA. BioSpectra provides custom cGMP purifications, acidifications, acid/base reactions, custom formulations and particle manipulation, along with documented regulatory support.
 
“BioSpectra is proud of its customer-focused, custom manufacturing capabilities which provide a unique combination of industry-leading quality – from process chemistry through finished end product,” said Richard Mutchler, president of BioSpectra. “Our clients rest assured knowing they are working with a partner who offers written, declared end-use statements detailing the product is designed, engineered, validated and manufactured solely for the purpose it’s being used. Therefore, we confirm in advance the strict controls with which BioSpectra governs its equipment, processes and products.”

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.